B+
Bull case
0%
Probability
Target price
$24.00
+64.7% vs current
WW
WW InternationalDNasdaq / Consumer Services
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
1%
Probability
Target price
$18.00
+23.5% vs current
B-
Bear case
0%
Probability
Target price
$10.00
-31.4% vs current
AI sentiment snapshot
Latest data as of 2026-07-03
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+65.7
Score
AI commentary
Primary-source tone is constructive but still monitoring-oriented. WW has supplied tangible operating evidence for clinical growth, ARPU improvement, guidance reaffirmation, and new GLP-1 access channels, yet the setup is not clean because behavioral declines persist and leadership is still in transition. Recent headline flow is active enough for medium buzz, but social coverage is not available in the packet and analyst-revision visibility remains thin, so confidence should stay moderate rather than high-conviction.
RankAlpha Sentiment Codex - 2026-07-03
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-15eventNext results should confirm whether debt repair and cash generation are still on trackHigh impact
The May 7 earnings release reaffirmed full-year 2026 guidance, disclosed $121 million of cash at March 31, and said Q2 debt-prepayment actions were expected to reduce debt by $42 million; the next company update is the clean checkpoint for whether balance-sheet repair is translating into better flexibility. [#SEC-8K-2026-05-07]
2026-09-30catalystMed+ access expanded through LillyDirect and Medicare bridgeHigh impact
WW added Med+ access through LillyDirect on June 4 and said on June 30 that Med+ will support Medicare members using the Medicare GLP-1 Bridge Program starting July 1, which can widen top-of-funnel and improve clinical subscriber adds if conversion holds. [#PR-2026-06-04] [#PR-2026-06-30]
2026-12-31catalystClinical growth and higher-ARPU mix still have to outrun Behavioral declineHigh impact
WW is showing real clinical traction, with Q1 2026 clinical subscription revenue up 32% year over year, clinical subscribers up 46%, Core+ back to growth, and ARPU up 13%, but total revenue still fell 10%; the longer thesis only works if clinical scale and premium mix can more durably offset secular pressure in the legacy Behavioral base. [#SEC-8K-2026-05-07] [#SEC-8K-2026-03-16]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-03 • Updated nightlySource: Internal modelMethodology